

You Are Cordially Invited to Attend a Professional Lecture

This promotional program is intended to exclusively educate healthcare professionals only



ZENPEP® (pancrelipase) Delayed-Release Capsules: Treating Exocrine Pancreatic Insufficiency

PRESENTED BY

Arin Newman, MD

Miami Beach, FL

Sponsored by Nestlé Health Science

Wednesday, April 01, 2026 at 6:00 PM

Desi Vega's Steakhouse

1950 North Highway 190, Covington, LA 70433-5158 Phone: (985) 276-4994



**Please RSVP for this program by using the following link or QR Code to the right:
NHSPProgramsRSVP.Com/SNHS2452**

On behalf of Nestlé Health Science, MedForce can accept RSVPs from HCPs via phone at 888-329-6709.

Please reference Meeting ID 2452.

For questions contact your Nestlé Health Science Representative Kathleen Eckstein Phone:(251) 424-4080

This promotional event is brought to you by Nestlé Health Science and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of Nestlé Health Science and the information being presented is consistent with FDA guidelines.

This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs).

Attendance by guests or spouses is not appropriate. It is Nestlé Health Science's policy to include only those HCPs involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. Nestlé Health Science's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. Nestlé Health Science abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from Nestlé Health Science. Please comply with applicable law.

INDICATIONS

ZENPEP® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Fibrosing Colonopathy

- Fibrosing colonopathy is a rare serious adverse reaction initially described in association with use of high-dose pancreatic enzyme products, usually with use over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis. Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day or 4,000 lipase units/g fat ingested/day).

**Please see additional Important Safety Information on reverse side and
accompanying full Prescribing Information.**



IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

Irritation to Oral Mucosa

- Crushing or chewing ZENPEP capsules or mixing the capsule contents in foods having a pH greater than 4.5 can cause irritation of the oral mucosa. Do not crush or chew capsules or capsule contents.

Hyperuricemia

- Pancreatic enzyme products contain purines that may increase blood uric acid levels. High dosages have been associated with hyperuricosuria and hyperuricemia.

Risk of Viral Transmission

- There is theoretical risk for transmission of viral disease. However, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.

Hypersensitivity Reactions

- Severe hypersensitivity reactions including anaphylaxis, asthma, hives, and pruritus have been reported with pancreatic enzyme products.
- Monitor patients with a known hypersensitivity reaction to proteins of porcine origin for hypersensitivity reactions during treatment with ZENPEP.

Adverse Reactions

- The most common adverse reactions ($\geq 6\%$ of patients treated with ZENPEP) were headache, contusion, cough, and early satiety.

Additional Important Safety Information

- Do not substitute other pancreatic enzyme products for ZENPEP.

Please see additional Important Safety Information on reverse side and accompanying full Prescribing Information.

You Are Cordially Invited to Attend a Professional Lecture

This promotional program is intended to exclusively educate healthcare professionals only



ZENPEP® (pancrelipase) Delayed-Release Capsules: Treating Exocrine Pancreatic Insufficiency

This promotional event is brought to you by Nestlé Health Science and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of Nestlé Health Science and the information being presented is consistent with FDA guidelines.

This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is Nestlé Health Science's policy to include only those HCPs involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. Nestlé Health Science's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. Nestlé Health Science abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from Nestlé Health Science. Please comply with applicable law.

INDICATIONS

ZENPEP® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Fibrosing Colonopathy

- Fibrosing colonopathy is a rare serious adverse reaction initially described in association with use of high-dose pancreatic enzyme products, usually with use over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis. Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day or 4,000 lipase units/g fat ingested/day).

Please see additional Important Safety Information on reverse side and
accompanying full Prescribing Information.

